CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 60 enrolled
Drug / intervention
Lung Ultrasound (LUS)other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04692779
NCT04692779N/ACompleted
CompareCT.gov

A Prospective Clinical Study to Explore the Mechanism of Patients' Response to Prone Positioning in ARDS Patients, Including COVID-19

Rush University Medical Center·observational·Posted Jan 5, 2021·Updated Oct 8, 2025

In Brief

An observational study evaluating Lung Ultrasound (LUS) for Covid19 and ARDS. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The proposed study will be conducted to investigate the mechanism of patients' responses to prone positioning with coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) and non-COVID-19 ARDS utilizing lung ultrasound.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19, ARDS
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJan 5, 2021
Enrollment StartJan 31, 2021
Primary CompletionJan 31, 2022
Study CompletionDec 6, 2024
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 5.5 years ago

Interventions

Lung Ultrasound (LUS)other

Enrolled subjects will undergo LUS 1 hour before and 1 hour after prone positioning by a trained clinician and will be assessed using a LUS score based on LUS pattern. LUS will then be performed again 1 hour before supination (16 hours) and assessed by a LUS score. This process will be repeated on the first 3 prone sessions. Patients will be enrolled in the study for 4 weeks in order to observe patient outcomes.